Previous Close | 7.10 |
Open | 7.10 |
Bid | 6.20 |
Ask | 6.90 |
Strike | 12.00 |
Expire Date | 2026-01-16 |
Day's Range | 7.10 - 7.10 |
Contract Range | N/A |
Volume | |
Open Interest | 45 |
ROCKVILLE, Md. & EDMONTON, Alberta, May 30, 2024--Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...
ROCKVILLE, Md. & EDMONTON, Alberta, May 14, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program.